What is at stake
Diseases that remain incurable and treatments that are often too aggressive highlight the urgent need for more effective, better-tolerated solutions. From cancer to rare diseases, the needs remain immense. This chair promises to accelerate the development of new therapeutic approaches — from biotherapies (RNA/DNA, gene and cell therapies) to innovative small molecules — shortening the path from discovery to proof of concept.
At the heart of this chair, chemistry makes the difference: it designs the delivery systems that bring therapies to the right place at the right time, and makes it possible to identify the most promising candidates quickly.
The expected impact is direct: more targeted medicines, fewer side effects and new solutions for patients who currently have none.
Strasbourg, a unique ecosystem
Strasbourg brings together a research chain that few sites can match: a pioneering role in vectorization and non-viral delivery (RNA/DNA) — the art of getting a therapy to the right place in the body. It also unites every stage required to discover a therapeutic molecule: design, screening and proof of concept. Access to advanced imaging tools and innovative molecular probes accelerates the identification and selection of the most promising candidates.
It sits at the centre of one of the most dynamic regional health-innovation ecosystems, including the Institut du Médicament de Strasbourg, from which roughly one start-up emerges each year. It is this continuity, from laboratory to drug candidate, that the chair will harness to shorten the path from discovery to the first patients.